Tailor-made drug treatment for children: creation of an infrastructure for data-sharing and population PK-PD modeling.

Rational dosing guidelines for drugs in pediatrics are urgently needed. To develop these guidelines, we use population pharmacokinetic-pharmacodynamic (PK-PD) modeling and simulation by: (i) optimization of clinical trial designs based on preliminary data; (ii) development and internal validation of population PK-PD models using sparse data; (iii) external validation using independent data; and (iv) prospective clinical evaluation. Optimized dosing regimens for specific drugs may then serve as a basis to develop dosing guidelines for existing or newly developed drugs with similar disposition and/or effect. In addition to modeling of drug disposition (PK) pathways, we emphasize the need for modeling of effect (PD) pathways and the use of a multidisciplinary infrastructure for data-sharing.

[1]  V. Hasselblad,et al.  Pediatric Antihypertensive Trial Failures: Analysis of End Points and Dose Range , 2008, Hypertension.

[2]  T. Johnson Modelling approaches to dose estimation in children. , 2005, British journal of clinical pharmacology.

[3]  S. Marsh,et al.  Developmental Changes in Human Liver CYP2D6 Expression , 2008, Drug Metabolism and Disposition.

[4]  France Mentré,et al.  Metrics for External Model Evaluation with an Application to the Population Pharmacokinetics of Gliclazide , 2006, Pharmaceutical Research.

[5]  Susan M Abdel-Rahman,et al.  Developmental pharmacology--drug disposition, action, and therapy in infants and children. , 2003, The New England journal of medicine.

[6]  Meindert Danhof,et al.  Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. , 2007, Annual review of pharmacology and toxicology.

[7]  G. Kearns,et al.  Pharmacokinetics of Gatifloxacin in Infants and Children , 2005, Antimicrobial Agents and Chemotherapy.

[8]  D. Tibboel,et al.  Pharmacokinetics and Pharmacodynamics of Midazolam and Metabolites in Nonventilated Infants after Craniofacial Surgery , 2006, Anesthesiology.

[9]  W. Hop,et al.  Use of Saliva in Therapeutic Drug Monitoring of Caffeine in Preterm Infants , 2001, Therapeutic drug monitoring.

[10]  G. Levy,et al.  Impact of pharmacodynamic variability on drug delivery(1). , 1998, Advanced drug delivery reviews.

[11]  E N Jonsson,et al.  Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. , 1999, Computer methods and programs in biomedicine.

[12]  A. van Hecken,et al.  Comparative pharmacokinetics of ceftazidime and moxalactam , 1982, Antimicrobial Agents and Chemotherapy.

[13]  Shinya Ito,et al.  Challenges for drug studies in children: CYP3A phenotyping as example. , 2009, Drug discovery today.

[14]  D. Tibboel,et al.  Propofol Pharmacokinetics and Pharmacodynamics for Depth of Sedation in Nonventilated Infants after Major Craniofacial Surgery , 2006, Anesthesiology.

[15]  Mats O. Karlsson,et al.  Three new residual error models for population PK/PD analyses , 1995, Journal of Pharmacokinetics and Biopharmaceutics.

[16]  D. Phelps E-ferol: what happened and what now? , 1984, Pediatrics.

[17]  Maurizio Bonati,et al.  Survey of unlicensed and off label drug use in paediatric wards in European countries , 2000, BMJ : British Medical Journal.

[18]  M Danhof,et al.  Relevance of the Application of Pharmacokinetic-Pharmacodynamic Modelling Concepts in Drug Development , 1997, Clinical pharmacokinetics.

[19]  D. Tibboel,et al.  Covariates of tramadol disposition in the first months of life. , 2008, British journal of anaesthesia.

[20]  Fatal cardiovascular collapse of infants receiving large amounts of chloramphenicol. , 1959, A.M.A. journal of diseases of children.

[21]  W. Hop,et al.  Ceftazidime pharmacokinetics in preterm infants: effect of postnatal age and postnatal exposure to indomethacin. , 1995, British journal of clinical pharmacology.

[22]  Lewis B. Sheiner,et al.  Building population pharmacokineticpharmacodynamic models. I. Models for covariate effects , 1992, Journal of Pharmacokinetics and Biopharmaceutics.

[23]  W. Silverman,et al.  A difference in mortality rate and incidence of kernicterus among premature infants allotted to two prophylactic antibacterial regimens. , 1956, Pediatrics.

[24]  K. Covinsky,et al.  Assessing the Generalizability of Prognostic Information , 1999, Annals of Internal Medicine.

[25]  S. Parker,et al.  The use of the dried blood spot sample in epidemiological studies. , 1999, Journal of clinical pathology.

[26]  D. Tibboel,et al.  Unapproved and off-label use of drugs in a children's hospital. , 2000, The New England journal of medicine.

[27]  J. Burns Research in children , 2003, Critical care medicine.

[28]  Michel Tod,et al.  Facilitation of Drug Evaluation in Children by Population Methods and Modelling , 2008, Clinical pharmacokinetics.

[29]  T. J. Preston,et al.  Induction of CYP1A2 activity by carbamazepine in children using the caffeine breath test. , 1998, British journal of clinical pharmacology.

[30]  Sihe Wang,et al.  Recent development in application of high performance liquid chromatography-tandem mass spectrometry in therapeutic drug monitoring of immunosuppressants. , 2008, Journal of immunological methods.

[31]  Phyllis N Butow,et al.  Clinical trials in children , 2004, The Lancet.

[32]  G H Guyatt,et al.  Users' guides to the medical literature: XXII: how to use articles about clinical decision rules. Evidence-Based Medicine Working Group. , 2000, JAMA.

[33]  B. Stricker,et al.  Unlicensed and off-label drug use in a paediatric ward of a general hospital in the Netherlands , 2002, European Journal of Clinical Pharmacology.

[34]  D. Tibboel,et al.  Pharmacogenetics and paediatric drug development: issues and consequences to labelling and dosing recommendations , 2007, Expert opinion on pharmacotherapy.

[35]  P. McNamara,et al.  Using ontogeny information to build predictive models for drug elimination. , 2008, Drug discovery today.

[36]  G. Kearns,et al.  Population Pharmacokinetic Model for Gatifloxacin in Pediatric Patients , 2007, Antimicrobial Agents and Chemotherapy.

[37]  J. Leeder Ontogeny of drug-metabolizing enzymes and its influence on the pathogenesis of adverse drug reactions in children , 2001 .